Who Owns Endonovo Therapeutics Company?

Endonovo Therapeutics Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Controls Endonovo Therapeutics?

Navigating the biotech landscape demands a deep understanding of company ownership. Uncover the key players shaping the future of Endonovo Therapeutics and its innovative approach to bioelectric medical devices. This investigation is particularly timely, considering the strategic spin-off of its SofPulse assets. Understanding Endonovo Therapeutics SWOT Analysis is key to understanding the company's position.

This exploration into Endonovo ownership will reveal the influence of founders, key investors, and public shareholders. We'll examine the impact of the SofPulse spin-off on the company's structure and the evolving dynamics of Endonovo stock. Discover insights into the current market capitalization, share structure, and the individuals steering Endonovo Therapeutics, including the CEO and the leadership team, to understand its financial performance and strategic direction.

The story of Endonovo Therapeutics, now focused on biotechnology, began in November 2008 as Hanover Asset Management, Inc. Understanding the early ownership structure of Endonovo is key to grasping its evolution from its initial form to its current state. The company's journey involved shifts in leadership and strategic direction, influencing its investor base and operational focus.

Garry Michael Kann, through Firebird Partners, played a crucial role in acquiring Hanover Asset Management's assets in 2008. He was instrumental in getting the company listed on the OTCBB in 2012. Currently, Alan Collier serves as the Chairman and CEO, bringing experience from IP Resources International, Inc. to his leadership role at Endonovo.

Early financial backing included a $3 million equity purchase agreement with Kodiak Capital Group, LLC in January 2015. This investment was intended for working capital and research and development. This early institutional support highlights the company's reliance on external funding to fuel its growth, particularly as it transitioned into the biotechnology sector.

Founding and Early Stages

Endonovo Therapeutics was incorporated in November 2008 as Hanover Asset Management, Inc. The initial ownership structure was shaped by the acquisition of assets by Garry Michael Kann through Firebird Partners.

Key Leadership

Garry Michael Kann played a crucial role in the early development of the company, leading to its listing on the OTCBB in 2012. Alan Collier, the current Chairman and CEO, joined after holding leadership positions at IP Resources International, Inc.

Early Investment

In January 2015, Endonovo Therapeutics secured a $3 million equity purchase agreement with Kodiak Capital Group, LLC. This funding supported working capital and research and development efforts.

Strategic Shift

The company's move from debt portfolio management to a biotechnology focus, particularly in medical devices and regenerative medicine, influenced its investor profile. This shift likely attracted investors interested in the biotech sector.

Ownership Evolution

The early ownership of Endonovo reflects a transition from its initial form to its current biotechnology focus. Understanding this evolution is crucial for assessing the company's trajectory.

Financial Backing

The $3 million investment from Kodiak Capital Group, LLC in 2015 was a key financial milestone. Such early investments are vital for supporting the company's growth.

Key Takeaways on Endonovo Ownership

The initial ownership of Endonovo Therapeutics was shaped by Garry Michael Kann's acquisition of assets and subsequent leadership. Early investments, like the one from Kodiak Capital Group, LLC, played a crucial role in funding the company's growth and research efforts. The company's strategic shift into biotechnology influenced its investor base and operational focus. For more insights, read about the Growth Strategy of Endonovo Therapeutics.

• Garry Michael Kann's role in the early stages was significant.
• The investment from Kodiak Capital Group, LLC provided essential capital.
• The transition to biotechnology impacted the company's strategic direction.
• Alan Collier's current leadership reflects a continuation of the company's evolution.

Endonovo Therapeutics SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Endonovo Therapeutics has evolved significantly since it became a publicly traded company. Listed on the OTC Markets (OTCQB: ENDV), the company's market capitalization as of June 6, 2025, is approximately $165,000, with around 1.1 billion shares outstanding. This reflects changes in the share structure, with the number of shares outstanding increasing from 396.75 million in September 2024 to 1,097.92 million by March 2025, indicating new share issuances.

A pivotal event impacting Endonovo's ownership is the planned spin-off of its medical device division, SofPulse, Inc. This strategic move, formalized through a binding Letter of Intent in March 2023 and an asset purchase agreement in March 2024, aims to unlock value. Existing shareholders are expected to retain their Endonovo ownership and receive an interest in the spun-off entity. This is a key factor in understanding who owns Endonovo and how the company plans to evolve.

Major stakeholders include institutional investors like Cavalry Fund and Bellridge Capital, who have been investors since May 2020 and July 2016, respectively. As of December 31, 2024, Family CFO Inc. held 60 shares, representing 0% ownership. The ownership structure also shows that insider ownership was reported at 8.41% with 26.8 million shares, while institutional ownership was negligible at 0.0001% with 360 shares. The remaining 91.59% of shares, or 291.9 million shares, are held by other owners. For more context, you can explore a Brief History of Endonovo Therapeutics.

Key Takeaways on Endonovo Therapeutics Ownership

Understanding Endonovo's ownership structure is crucial for investors and stakeholders.

• The company is publicly traded on the OTC Markets.
• Share count has increased due to new issuances.
• Major stakeholders include institutional investors.
• The spin-off of SofPulse, Inc. will significantly impact ownership.

Endonovo Therapeutics PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current management structure of Endonovo Therapeutics is primarily overseen by its sole director, who also acts as the CEO. This individual, currently Alan Collier, holds considerable voting power within the company. Decisions regarding the company's management are made by the board of directors and officers. Understanding the Endonovo ownership structure is crucial for anyone looking into Endonovo stock or considering becoming Endonovo investors.

Endonovo Therapeutics has a unique voting structure, including Series AA Super Voting Preferred Stock. As of December 31, 2018, there were 25,000 shares of Series AA Preferred stock outstanding, with each share providing the holder with 100,000 votes. This special voting right gives significant control to the holders of these preferred shares. The board has the power to issue additional shares, potentially affecting the distribution of voting power. For more details, you can explore Revenue Streams & Business Model of Endonovo Therapeutics.

The scientific advisory board includes experts like Steven Levin, M.D., who was appointed in August 2019 to provide expertise in anesthesiology and pain management. There is no recent public information available regarding proxy battles or activist investor campaigns affecting Endonovo Therapeutics. Understanding the Endonovo management team is key to assessing the company's direction and potential.

Key Takeaways on Endonovo's Governance

The voting structure is complex, with super-voting preferred shares. The CEO holds significant voting power. The board composition includes key figures in leadership and corporate development.

• Alan Collier serves as Chairman and CEO.
• Garry Michael Kann leads Corporate Development.
• Ira Weisberg is the President and Chief Commercial Officer of the Medical Division.
• The company has a scientific advisory board for specialized expertise.

Endonovo Therapeutics Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, significant changes have reshaped the ownership landscape of Endonovo Therapeutics. A key development is the spin-off of SofPulse, Inc., its medical device division. This strategic move, formalized in March 2024 with an asset purchase agreement, aims to boost SofPulse's commercialization and potentially secure a NASDAQ listing. Existing Endonovo shareholders are expected to gain an interest in the spun-off entity, with a portion of the new company's shares possibly allocated to debt holders.

Endonovo ownership has seen shifts, including an increase in outstanding shares, from 396.75 million in September 2024 to 1,097.92 million by March 2025, reflecting new share issuances. While institutional ownership remains low, some institutional investors have shown interest. Insider ownership was reported at 8.41%. These trends are indicative of the company's efforts to reorganize assets and potentially draw in new Endonovo investors to both entities.

Endonovo management has also pursued capital-raising initiatives, such as a Regulation A Tier 2 offering in 2023, which could broaden ownership among smaller investors. Recent SEC filings in 2024 and 2025 include current and quarterly reports, with a notable SEC staff action in September 2024. For more insights into the strategic direction, consider exploring the Growth Strategy of Endonovo Therapeutics.

Who is the CEO of Endonovo Therapeutics?

The future President and CEO of SofPulse, Inc., the spun-off medical device division, is designated as Ira Weisberg.

Endonovo Therapeutics stock symbol

The stock symbol for Endonovo Therapeutics is likely to remain the same, but this information may vary depending on the stock exchange.

How to invest in Endonovo Therapeutics

Investing in Endonovo Therapeutics involves purchasing shares through a brokerage account. Investors should conduct thorough research and consider consulting a financial advisor.

Endonovo Therapeutics financial performance

Financial performance details can be found in the company's SEC filings, including current and quarterly reports, which provide insights into revenue, expenses, and profitability.

Endonovo Therapeutics Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs